Zcash Miner's $1M Bet on a Heart Monitor Company Is a Merger Survival Move

Here's a sentence you won't read twice: a Zcash miner just paid $999,998.46 for 9.4% of a Nasdaq-listed medical device company. That's not a typo. The buyer is Fortitude Mining, Digital Currency Group's Zcash subsidiary. The target is HeartSciences, a company that builds software for cardiovascular screening. And the deal that connects them is a proposed merger where DCG would end up with about 95% of the combined company.

The money moved on Aug. 12 as a private placement. Fortitude bought 411,522 HeartSciences common shares at $2.43 each. That's a 22% premium to the closing price that day. HeartSciences says the cash covers operating expenses while the merger waits for shareholder approval. The investment doesn't change the exchange ratio, so Fortitude's equity holders won't get any extra closing shares for the $1M injection.

The $1M Bridge

Let's zoom out. Fortitude is a miner. Its business is burning electricity to secure the Zcash network. HeartSciences is a clinical software company. Its business is selling FDA-cleared tools to cardiologists. On paper, these two have nothing in common. That's the point.

This isn't a partnership announcement. It's a convergence. A crypto miner wants a public listing. HeartSciences is a Nasdaq shell with a real product but a precarious balance sheet. The merger gives DCG a public vehicle for its mining operations, and it gives HeartSciences shareholders a ticket on a volatile crypto ride. The $1M placement is the grease.

But look closer at the terms. A 22% premium to market price for a stock that's about to be diluted into a 5% slice of a combined entity? That's not an investment thesis. It's a bridge payment. Fortitude is paying HeartSciences to stay solvent long enough to get the deal done.

The risk is right there in the proxy. If the merger fails, HeartSciences warns it may have limited ability to continue operating. It could need another strategic transaction, and if no viable alternative emerges, the company may liquidate. No assurance that cash would remain for shareholders. Fortitude's $1M doesn't change that. It just buys time.

What Fortitude Is Really Buying

So why do it? The obvious answer is deal certainty. A dead target can't vote itself into a merger. By injecting cash at a premium, Fortitude keeps HeartSciences breathing and signals commitment. It also gives Fortitude a direct equity stake, which means it controls more of the outcome than the exchange ratio alone would allow.

But here's the part that should bother you. Fortitude reported $8.5M in adjusted EBITDA for recent periods. Its GAAP financials tell a different story: a $9.5M net loss that includes a $10.3M mining-equipment impairment. That's the difference between saying you're profitable and doing the accounting honestly. The machines were worth less than their purchase price, and Fortitude had to write them down. The adjusted EBITDA number is a non-GAAP measure, so it strips out that reality.

What does that mean for the merger? It means the combined company's financial health depends on Zcash hashrate growth and token prices, not on heart monitors. HeartSciences shareholders are being asked to swap a stable, if struggling, medical software business for a piece of a mining operation with a history of equipment write-downs and non-GAAP optimism.

The proxy still has blank fields as of Aug. 20. No special meeting date. No record date. The companies expect to close in the second half of 2026, but that's a target window, not a promise. In crypto time, that's an eternity. In SEC time, it's a gauntlet.

The Takeaway

Here's the thing about this deal structure: Fortitude is paying $1M for a 9.4% stake in a company that will soon own 5% of the combined entity. That math only works if the merger closes. If it doesn't, HeartSciences could liquidate, and the $1M becomes a charitable donation to a sinking ship.

That's the brutal reality of reverse mergers in the crypto-mining era. The premium price isn't about value. It's about keeping a counterparty alive. Fortitude needs HeartSciences more than HeartSciences needs Fortitude's software expertise, because without the target, there's no listing, no public market access, no exit for DCG's mining investors.

For HeartSciences shareholders, the math is simpler. They're being asked to accept a 5% stake in a mining company that just paid a 22% premium to buy their stock. That premium is the only liquidity they'll see for a while. And if the deal falls apart, they're left with a company that explicitly says it might not survive.

So who wins? Fortitude, if the merger closes. DCG, if Zcash prices hold. HeartSciences shareholders, only if they believe the combined entity trades better than the standalone medical software company would. That's a bet on crypto volatility, not on cardiac screening.

This isn't a partnership announcement. It's a convergence. And in that convergence, the $1M private placement is the clearest signal yet that public crypto miners are willing to pay a premium for survival, as long as they get to control the currency that pays for it.